Advertisement

Medical Oncology

, 31:48 | Cite as

Serum CA125 level predicts prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy

  • Yue-Can ZengEmail author
  • Rong Wu
  • Si-Liang Wang
  • Feng Chi
  • Rui Xing
  • Wei-Song Cai
  • Guo-Liang Fan
  • Yu-Chen Fan
  • Wen-Zhao Zhong
  • Li-Na Wu
  • Xiao-Dong Chen
  • Huan-Huan Chen
  • Yu-Ping Xiao
Original Paper
  • 234 Downloads

Abstract

This study was to evaluate the effect of serum CA125 level on the prognosis of patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy. Sixty-six patients with multiple brain metastases from non-small cell lung cancer before and after treatment of radiotherapy were reviewed retrospectively. Radiotherapy was given to the whole brain using opposed 6MV lateral beams with a dose of 30 Gy in 15 fractions in 3 weeks. Elevated CA125 was defined as >35 U/mL. The survival rate was calculated using the Kaplan–Meier method, and the univariate and multivariate analyses were used to identify significant factors associated with prognosis, using a Cox proportional hazards model. During the median (range) follow-up of 1.25 (0.25–2.50) years, 62 patients died from non-small cell lung cancer; the 1-year cancer-specific survival (CSS) rate was 43.08 %. Thirty patients had a high CA125 level before chemoradiotherapy (>35U/mL), and their CSS rate was significantly worse than that in the remaining patients (P = 0.024). Multivariate analysis showed that CA125 level, number of metastases and total tumor volume were independent prognostic indicators for CSS, with a hazard ratio of 1.99, 1.67 and 2.02, respectively. The elevation of CA125 before treatment predicts a poor prognosis in patients with multiple brain metastases from non-small cell lung cancer before and after treatment of whole-brain radiotherapy.

Keywords

CA125 Non-small cell lung cancer Whole-brain radiotherapy Cancer-specific survival 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81201803).

Conflict of interest

None.

References

  1. 1.
    Ryan GF, Ball DL, Smith JG. Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys. 1995;31(2):273–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Sen M, Demiral AS, Cetingöz R, et al. Prognostic factors in lung cancer with brain metastasis. Radiother Oncol. 1998;46(1):33–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer. 2001;32(2):129–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1980;6(1):1–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol. 1980;7(6):529–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol. 2002;20(16):3445–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Antoni D, Noël G, Mornex F. The role of whole brain radiation therapy for brain metastases. Bull Cancer. 2013;100(1):15–22.PubMedGoogle Scholar
  9. 9.
    Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494–500.PubMedCrossRefGoogle Scholar
  10. 10.
    Juretzka MM, Barakat RR, Chi DS, et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2007;104(1):176–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Nakata B, Hirakawa YS, Chung K, et al. Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer. 1998;83(12):2488–92.PubMedCrossRefGoogle Scholar
  12. 12.
    Fan Y, Huang Z, Fang L, et al. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther. 2013;4(6):1789–803.Google Scholar
  13. 13.
    Ojerholm E, Lee JY, Kolker J, Lustig R, Dorsey JF, Alonso-Basanta M. Gamma Knife radiosurgery to four or more brain metastases in patients without prior intracranial radiation or surgery. Cancer Med. 2014;3(3):565–71.Google Scholar
  14. 14.
    Kong DS, Lee JI, Im YS, Nam DH, Park K, Kim JH. Differential impact of whole-brain radiotherapy added to radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 2010;78(2):385–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Rades D, Bohlen G, Pluemer A, et al. Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer. 2007;109(12):2515–21.PubMedCrossRefGoogle Scholar
  16. 16.
    Badiyan SN, Ferraro DJ, Yaddanapudi S, et al. Impact of time of day on outcomes after stereotactic radiosurgery for non-small cell lung cancer brain metastases. Cancer. 2013;119(19):3563–9.PubMedGoogle Scholar
  17. 17.
    Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M, Iio A. Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer. 1990;62(4):676–8.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Buccheri G, Ferrigno D. Lung tumour markers in oncology practice: a study of TPA and CA125. Br J Cancer. 2002;87(10):1112–8.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Zhang D, Yu M, Xu T, Xiong B. Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population. Hepatogastroenterology. 2013;60(126):1297–301.PubMedGoogle Scholar
  20. 20.
    Cedrés S, Nuñez I, Longo M, et al. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011;12(3):172–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Goonewardene TI, Hall MR, Rustin GJ. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8(9):813–21.PubMedCrossRefGoogle Scholar
  22. 22.
    Nieder C, Grosu AL, Marienhagen K, et al. Non-small cell lung cancer histological subtype has prognostic impact in patients with brain metastases. Med Oncol. 2012;29(4):2664–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Yue-Can Zeng
    • 1
    Email author
  • Rong Wu
    • 1
  • Si-Liang Wang
    • 1
  • Feng Chi
    • 1
  • Rui Xing
    • 1
  • Wei-Song Cai
    • 1
  • Guo-Liang Fan
    • 2
  • Yu-Chen Fan
    • 3
  • Wen-Zhao Zhong
    • 4
  • Li-Na Wu
    • 1
  • Xiao-Dong Chen
    • 1
  • Huan-Huan Chen
    • 1
  • Yu-Ping Xiao
    • 5
  1. 1.Department of Medical OncologyShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Department of OtorhinolaryngologyHarbin First HospitalHarbinChina
  3. 3.Department of HepatologyQilu Hospital of Shandong UniversityJinanChina
  4. 4.Lung Cancer Research Institute and Cancer CenterGuangdong Provincial People’s HospitalGuangzhouChina
  5. 5.Cancer InstituteNo. 1 Hospital of China Medical UniversityShenyangChina

Personalised recommendations